Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study

Iveson, Timothy, Dr ; Donehower, Ross C, MD ; Davidenko, Irina, MD ; Tjulandin, Sergey, Prof ; Deptala, Andrzej, MD ; Harrison, Mark, MD ; Nirni, Somanath, MD ; Lakshmaiah, Kuntegowdanahalli, MD ; Thomas, Anne, Prof ; Jiang, Yizhou, PhD ; Zhu, Min, PhD ; Tang, Rui, PhD ; Anderson, Abraham, PhD ; Dubey, Sarita, MD ; Oliner, Kelly S, PhD ; Loh, Elwyn, MD

The lancet oncology, 2014-08, Vol.15 (9), p.1007-1018 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível